about
Zebrafish as a model for leukemia and other hematopoietic disordersAcute toxicity of nickel nanoparticles in rats after intravenous injectionInhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiationSingle-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia.MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitorsInhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells.Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.Synthetic genetic targeting of genome instability in cancer.Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.G-quadruplex structures in the human genome as novel therapeutic targets.In vitro and in vivo evaluation of the toxicities induced by metallic nickel nano and fine particles.AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB.Detection of G-type density in promoter sequence of colon cancer oncogenes and tumor suppressor genes.Vitamin K2 and cotylenin A synergistically induce monocytic differentiation and growth arrest along with the suppression of c-MYC expression and induction of cyclin G2 expression in human leukemia HL-60 cells.MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease
P2860
Q28081638-7EDDC9D0-DDDB-47B0-A0B5-E0CB5523A771Q28397767-218FF8A8-F476-42B2-9C06-8BB8689CFA3AQ28542016-733E9D38-9C63-4099-943B-7FB1E4D5554DQ33800102-29638B31-5366-4BFC-9EBB-CD7743E08E9CQ35006000-63E29DC8-E164-452B-8B72-C622DB0A75D5Q36629461-A5A6B4B2-18CB-4CCB-999F-C594322F2745Q37109671-0B5ACBE8-E8EF-43A2-B1F3-62F37C829572Q37226478-7FB19C96-CF7E-4F36-BDB3-D3DF25DAE7CEQ37624838-6A26A5CE-ED10-47D4-9D95-0889932816D0Q38151013-0CA5E3F8-F288-4C52-9316-C86A8DE2128EQ38783468-58F4B47D-CD1F-4FCD-9907-CBC9879CD2B5Q39415910-F0AF8BA5-7B7E-4770-881B-2918322A17B7Q40674785-CEC9B342-EFC8-464D-8E3E-6E1BEDF60701Q41514143-BA22D19C-C52A-4C61-B4D2-22AFAB37B5D8Q45742884-60AC2587-B4E0-483C-9F99-B4ED0AEB097BQ58699279-5A787187-6B99-4B1E-A51C-BC166525EDEC
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
MYC oncogene in myeloid neoplasias.
@en
type
label
MYC oncogene in myeloid neoplasias.
@en
prefLabel
MYC oncogene in myeloid neoplasias.
@en
P2093
P2860
P1476
MYC oncogene in myeloid neoplasias
@en
P2093
Ana Batlle
M Dolores Delgado
Marta Albajar
P2860
P2888
P356
10.1007/S12094-012-0926-8
P577
2012-08-22T00:00:00Z